What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Drug: SOB100 Participants will receive SOB100 and evaluate the safety and tolerability of SOB100 during the dose escalation phase.”In the company’s words, NCT07219940 on ClinicalTrials.gov
- Tested for
- Exosome, Targeted Therapy
- Main trialPhase 1
- “The investigational drug, SOB100, is an HLA-G targeted exosome equipped with a nanobody namely anti-HLA-G VHH on the exosome membrane. This is a Phase I dose escalation study to exam the tolerability, safety, and pharmacokinetics in healthy subjects.”In the company’s words, NCT07219940 on ClinicalTrials.gov
Coming up1
- DecPhase 1 trial completes · ClinicalTrials.gov
Changes1
Last 90 days- 19 NovStatus changed: Recruiting to Active, not recruiting · ClinicalTrials.gov NCT07219940
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Active, not recruiting | Dec 2026 | A Study to Investigate HLA-G Targeted Exosome (SOB100) in Healthy Subjects |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 20 Nov 2026 · EU trials register (CTIS) updated 20 Nov 2026 · openFDA updated 20 Nov 2026